



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/352, A61P 9/00, 9/10, 19/10	A1	(11) International Publication Number: WO 00/64438 (43) International Publication Date: 2 November 2000 (02.11.00)
(21) International Application Number: PCT/AU00/00384 (22) International Filing Date: 27 April 2000 (27.04.00) (30) Priority Data: PQ 0083 28 April 1999 (28.04.99) AU (71) Applicant (for all designated States except US): NOVOGEN RESEARCH PTY LTD [AU/AU]; 140 Wicks Road, North Ryde, NSW 2113 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): KELLY, Graham, Edmund [AU/AU]; 1,47 Coolawin Road, Northbridge, NSW 2063 (AU). HUSBAND, Alan, James [AU/AU]; 13 Marana Road, Northbridge, NSW 2063 (AU). (74) Agents: STEARNE, Peter et al.; Davies Collison Cave, Level 10, 10 Barrack Street, Sydney, NSW 2000 (AU).	(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	

(54) Title: CARDIOVASCULAR AND BONE TREATMENT USING ISOFLAVONES**(57) Abstract**

Compositions comprising formononetin and/or one or more isoflavones selected from biochanin, genistein and daidzein, in a therapeutically effective ratio of formononetin to said isoflavones of 15:1 to 2:1, optionally in association with one or more carriers, excipients, auxiliaries and/or diluents are described. Also described are methods of treatment involving such compositions including the prevention and/or treatment of cardiovascular disease, the beneficial alteration of blood lipoprotein levels, or a reduction in the risk of vascular disease, or a reduction in the risk of coronary heart disease, or a reduction in the risk of arteriosclerosis, or in the beneficial alteration or maintenance of bone density such as in the prevention or treatment of osteoporosis, and/or in the prevention and/or treatment of bone fracture.